产品中心

产品货号

产品名称

规格

销售价

会员价

货期

产地

订购

C307

Recombinant Human CD106/VCAM-1/L1CAM

10ug

400

360

现货

国产

C307

Recombinant Human CD106/VCAM-1/L1CAM

50ug

1200

1080

现货

国产

C307

Recombinant Human CD106/VCAM-1/L1CAM

500ug

12320

11088

现货

国产

C307

Recombinant Human CD106/VCAM-1/L1CAM

1mg

17600

15840

现货

国产

C307

Recombinant Human Vascular Cell Adhesion Protein 1/VCAM-1/L1CAM

10ug

400

360

现货

国产

C307

Recombinant Human Vascular Cell Adhesion Protein 1/VCAM-1/L1CAM

50ug

1200

1080

现货

国产

C307

Recombinant Human Vascular Cell Adhesion Protein 1/VCAM-1/L1CAM

500ug

12320

11088

现货

国产

C307

Recombinant Human Vascular Cell Adhesion Protein 1/VCAM-1/L1CAM

1mg

17600

15840

现货

国产

  • 产品简介
  • 使用说明
  • 相关产品
  • 参考文献
  • 购买咨询
  • Catalog# C307
    Source HEK293
    Description Recombinant Human Vascular Cell Adhesion Protein 1/VCAM-1 is produced by mammalian expression system in human cells. The target protein is expressed with sequence (F25-E698) of Human VCAM1 fused with a polyhistidine tag at the C-terminus.
    Names Vascular Cell Adhesion Protein 1, V-CAM 1, VCAM-1, INCAM-100, CD106, VCAM1, L1CAM
    Accession # P19320
    Formulation Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, 2mM CaCl2, 2mM MgCl2, 5% Threhalose, pH 7.2
    Shipping The product is shipped at ambient temperature.
    Reconstitution Always centrifuge tubes before opening. Do not mix by vortex or pipetting.
    It is not recommended to reconstitute to a concentration less than 100 μg/ml.
    Dissolve the lyophilized protein in 1X PBS.
    Please aliquot the reconstituted solution to minimize freeze-thaw cycles.
    Storage Lyophilized protein should be stored at < -20°C, though stable at room temperature for 3 weeks.
    Reconstituted protein solution can be stored at 4-7°C for 2-7 days.
    Aliquots of reconstituted samples are stable at < -20°C for 3 months.
    Purity Greater than 95% as determined by SEC-HPLC and reducing SDS-PAGE.
    Endotoxin Less than 0.1 ng/µg (1 IEU/µg).
    Amino Acid Sequence
    FKIETTPESRYLAQIGDSVSLTCSTTGCESPFFSWRTQIDSPLNGKVTNEGTTSTLTMNPVSFGN EHSYLCTATCESRKLEKGIQVEIYSFPKDPEIHLSGPLEAGKPITVKCSVADVYPFDRLEIDLLK GDHLMKSQEFLEDADRKSLETKSLEVTFTPVIEDIGKVLVCRAKLHIDEMDSVPTVRQAVKELQV YISPKNTVISVNPSTKLQEGGSVTMTCSSEGLPAPEIFWSKKLDNGNLQHLSGNATLTLIAMRME DSGIYVCEGVNLIGKNRKEVELIVQEKPFTVEISPGPRIAAQIGDSVMLTCSVMGCESPSFSWRT QIDSPLSGKVRSEGTNSTLTLSPVSFENEHSYLCTVTCGHKKLEKGIQVELYSFPRDPEIEMSGG LVNGSSVTVSCKVPSVYPLDRLEIELLKGETILENIEFLEDTDMKSLENKSLEMTFIPTIEDTGK ALVCQAKLHIDDMEFEPKQRQSTQTLYVNVAPRDTTVLVSPSSILEEGSSVNMTCLSQGFPAPKI LWSRQLPNGELQPLSENATLTLISTKMEDSGVYLCEGINQAGRSRKEVELIIQVTPKDIKLTAFP SESVKEGDTVIISCTCGNVPETWIILKKKAETGDTVLKSIDGAYTIRKAQLKDAGVYECESKNKV GSQLRSLTLDVQGRENNKDYFSPEVDHHHHHH
    Background VCAM-1 is a single-pass type I membrane protein, contains 7 Ig-like C2-type domains. It is an endothelial ligand for very late antigen-4 (VLA-4) and α4ß7 integrin expressed on leukocytes, and thus mediates leukocyte-endothelial cell adhesion and signal transduction. VCAM-1 expression is induced on endothelial cells during inflammatory bowel disease, atherosclerosis, allograft rejection, infection, and asthmatic responses. During these responses, VCAM-1 forms a scaffold for leukocyte migration. VCAM-1 also activates signals within endothelial cells resulting in the opening of an 'endothelial cell gate' through which leukocytes migrate. VCAM-1 has been identified as a potential anti-inflammatory therapeutic target, the hypothesis being that reduced expression of VCAM-1 will slow the development of atherosclerosis. In addition, VCAM-1-activated signals in endothelial cells are regulated by cytokines indicating that it is important to consider both endothelial cell adhesion molecule expression and function during inflammatory processes.